Related Experiment Videos
Bone density changes with once weekly risedronate in postmenopausal women
Miriam F Delaney1, Shelley Hurwitz, Jacyln Shaw
1Endocrine-Hypertension Division, Brigham and Women's Hospital, Boston, MA 02115, USA. mdelaney3@partners.org
Summary
Weekly risedronate 30 mg improved bone mineral density (BMD) in postmenopausal women. This dosing regimen was well-tolerated, showing a low incidence of gastrointestinal side effects, even in patients with prior bisphosphonate intolerance.
Area of Science:
- Endocrinology
- Rheumatology
- Pharmacology
Background:
- Daily bisphosphonates for postmenopausal osteoporosis can cause gastrointestinal (GI) symptoms.
- Weekly bisphosphonate administration may offer improved GI tolerability.
- Risedronate 30 mg is approved for Paget's disease of bone.
Purpose of the Study:
- To assess the GI tolerability of risedronate 30 mg taken once weekly.
- To evaluate the effect of this regimen on bone mineral density (BMD) in postmenopausal women.
Main Methods:
- Retrospective review of 150 postmenopausal women with low BMD treated with risedronate 30 mg weekly.
- Analysis of GI symptoms at baseline and during treatment.
- BMD measurements at baseline and follow-up in a subset of 36 patients.
Main Results:
- Only 1 of 32 patients with prior GI symptoms or bisphosphonate intolerance developed GI issues.
- BMD increased by 1.9% at the trochanter (p=0.02) and 2.1% at the total hip (p=0.001) in 36 patients.
- Risedronate 30 mg weekly was well-tolerated with a low incidence of GI side effects.
Conclusions:
- Risedronate 30 mg once weekly is an effective treatment for increasing BMD at the trochanter and total hip.
- This weekly dosing regimen demonstrates good GI tolerability in postmenopausal women, including those with prior bisphosphonate intolerance.